Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

The company is currently recruiting participants to demonstrate the benefits of its BioREtain technology.

BioStem Launches BR-AM-DFU Clinical Trial for Non-Healing Diabetic Foot Ulcers 

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Designed to mimic natural tissue scaffolds, DermiSphere hDRT offers innovative support for cellular infiltration and healing in reconstructive surgery.

FDA Approves Collagen-Based DermiSphere Hydrogel

The innovative technology is unlocking new possibilities in dermatology by improving the solubility and permeability of drugs for topical use.

Ionic Liquids Boost Skin Drug Delivery

The synergistic approach reduced submental fullness, enhanced mandible line definition, and improved chin projection.

Combination Treatment of Cryolipolysis and Hyaluronic Acid Fillers Greatly Enhances Jawline

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

It is important dermatologists learn to recognize the clinical findings of dermatophytomas and distinguish them from other onychomycosis subtypes because the recommended treatments differ. 

Dermatophytoma: A Diagnosis That You Do Not Want to Miss 

Cognizance and certain clues may help dermatologists in recognizing antifungal-resistant dermatophyte infections. 

Emergence of Antifungal-Resistant Dermatophyte Infections

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

The upcoming year is poised to bring significant advancements in dermatologic treatments, with 3 highly anticipated Prescription Drug User Fee Act (PDUFA) dates on the horizon. These therapies address pressing unmet needs in dermatology and promise to enhance patient care.

First, dupilumab (Dupixent) has the potential to become the first targeted therapy for chronic spontaneous urticaria in over a decade. Backed by strong data from the LIBERTY-CUPID clinical trials, Dupixent offers hope for patients struggling with uncontrolled itching and hives.

Next, prademagenezamikeracel (pz-cel) may revolutionize care for patients with recessive dystrophic epidermolysis bullosa, a rare and debilitating condition. The FDA's acceptance of Abeona Therapeutics’ resubmitted Biologics License Application puts this innovative gene therapy one step closer to addressing unmet needs in wound healing and pain management.

Finally, roflumilast foam 0.3% (Zoryve) offers a steroid-free, easy-to-apply option for treating scalp and body psoriasis. Results from the ARRECTOR phase 3 trial highlight its potential to clear plaques and relieve symptoms in hair-bearing and other hard-to-treat areas.

We want to hear from you. Which of these PDUFA dates are you most excited about, and why? Cast your vote in our poll below and share your thoughts with the 

Dupilumab (Dupixent; Sanofi) for chronic spontaneous urticaria

Pz-cel (prademagenezamikeracel) (Abeona Therapeutics) for recessive dystrophic epidermolysis bullosa

Roflumilast foam 0.3% (Zoryve; Arcutis Biotherapeutics) for scalp and body psoriasis

Want to share more of your insights and perspectives with us? Email our team at 

Dupixent (dupilumab) sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (CSU). News release. Regeneron. November 15, 2024. Accessed January 3, 2025. 

https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-sbla-accepted-fda-review-treatment-chronic

Abeona Therapeutics announces FDA accepts and grants Priority Review for pz-cel biologics license application (BLA). News release. Abeona Therapeutics. November 27, 2023. Accessed January 3, 2025. 

https://investors.abeonatherapeutics.com/press-releases/detail/268/abeona-therapeutics-announces-fda-accepts-and-grants

Arcutis submits supplemental new drug application for ZORYVE (roflumilast) foam to the FDA for the treatment of scalp and body psoriasis in adults and adolescents ages 12 and over. News release. Arcutis Biotherapeutics, Inc. July 23, 2024. Accessed January 3, 2025. 

https://www.arcutis.com/arcutis-submits-supplemental-new-drug-application-for-zoryve-roflumilast-foam-to-the-fda-for-the-treatment-of-scalp-and-body-psoriasis-in-adults-and-adolescents-ages-12-and-over/

Significant advancements in dermatologic treatments are anticipated with three upcoming Prescription Drug User Fee Act (PDUFA) dates. Dupilumab (Dupixent) could become the first targeted therapy for chronic spontaneous urticaria in over a decade, offering hope for patients with uncontrolled symptoms. Prademagenezamikeracel (pz-cel) may revolutionize care for recessive dystrophic epidermolysis bullosa, addressing unmet needs in wound healing and pain management. Roflumilast foam 0.3% (Zoryve) provides a steroid-free option for treating scalp and body psoriasis, showing promise in clearing plaques and relieving symptoms.

Share your insights and anticipation with us.

Polls 

POLL: Which Anticipated Drug Approval/PDUFA Date Are You Most Looking Forward to in 2025?

From Clinic to Practice: Translating AD Trial Data

Dermatology experts provide critical analysis and interpretation of data from clinical trials to inform evidence-based practice in the field.

I like to think about the year-end holiday season as equal parts fun and chaos. The joy of being together with friends and family, compounded by the inherent stress that comes with squeezing out every last ounce of joy of merriment from the waning year, is a quintessential American experience: Nobody can quite ride that juxtaposition like we do. Of course, this concept was never apparent to me as a child, but now as a parent of 2 young children, the pressure is on. For parents, I think much of this feeling comes from wanting to give our children the best holiday experience possible, which usually takes the form of celebrating our unique traditions. Traditions are so important to us all—no matter what form they take—and this is the one time of year we get the chance to take a tiny break from our fast-paced lives to celebrate the differences that bring us together (yet another beautifully American juxtaposition).

In our house we’re blessed to be a multilingual, multicultural melting pot with a perfect storm of celebrations from around the world. Over the course of several months stretching into the new year (oh the joy of solar and lunar calendars), we get to enjoy many familiar holidays (and some less familiar) from India, Venezuela, China, and the good old USA, with our own spin. Some examples include the following:

The 9 nights of Navratri, dancing to the beats of garba and raas for days on end

The 5 days of Diwali, when salty fried snacks and sweet barfi fill every corner of the kitchen

Thanksgiving, when nothing goes better with roast turkey than biryani, arepas, and char siu

Christmas, when assembly line construction of hallacas and pan de jamón while singing along to “Mi Burrito Sabanero” doesn’t count as child labor

New Year’s Eve, when 12 grapes in 1 minute can make all your wishes come true

Lunar new year, armed with an unending supply of lai see (aka red envelopes) and fireworks

And that’s just a sample of a few months out of our year! I love that I get to pass on old traditions and make new ones with my family based around food, festivals, music, dance, religion, ideology, and just plain togetherness. Our story can’t be explained by any one of these alone, and that is what diversity is all about.

That word, diversity, has been a frequent part of our lexicon in dermatology over the past few years, as we have grappled with how we move our field forward and embrace what brings us together (the physiology and pathology of the skin) while acknowledging the disparities that can make the individual dermatologic experience so distinct and uneven in our country. In medicine, we’ve spent so long trying to identify the singular lens under which all our differences and inequities can be explained (It’s skin color! It’s race! it’s ethnicity! It’s all of them! It’s none of them!), only to realize that there probably isn’t one perfect answer to fully explain concepts like diagnostic inaccuracy, treatment delays, and poorer outcomes. What is clear is that the house of medicine has unfortunately relied too long on using isolated social constructs to support purported intrinsic biological and genetic differences when, as it turns out, we’re not all that dissimilar from one another. We are all human beings, after all.

So how can we better understand many dermatologic disparities when it comes to care, treatment, and outcomes? Well, diversity isn’t just for our holiday traditions; it shapes disease risk and the individual experience. Beyond our cells, proteins, and genes, we are the sum of how we look, where we live, how much money we have, our health care access, and our opportunity for education in a system with variable social, public, economic, and governmental policies and cultural and society values. And our story can’t be told with just one of these elements.

While we have our work cut out for us, keep the faith. You’ve heard great stories in 

 all year about individuals trying to explore and address these concepts as they relate to the broad spectrum of dermatologic diseases. And you’ll continue to read even more in the coming year, when words will hopefully lead to more action and more change. We’re evolving dermatology in real time, and 2025 looks bright.

From the holidays, to dermatology, and beyond:

, is a clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School in Illinois and founder and director of the Center for Medical Dermatology and Immunology Research.

The holiday season embodies both joy and chaos, with traditions playing a crucial role in family celebrations. A multicultural household can experience a variety of global festivities, enriching the holiday experience. In dermatology, diversity is a key theme, highlighting the need to understand disparities in care and outcomes. The field has long relied on social constructs to explain differences, but a broader perspective is necessary. Dermatology must consider factors beyond biology, such as socioeconomic and cultural influences, to address disparities. The future of dermatology promises continued exploration and positive change.

Fall Editor in Chief Raj Chovatiya, MD, PhD, MSCI, celebrates the joy of diverse traditions and reflects on the path to equity in dermatology as we move toward a brighter 2025.

Letter From the Editor: Embrace Your Story

Evaluating Treatment Efficacy: Identifying and Managing AD Flares in Systemic Therapy Patients

Key opinion leaders in the management of dermatological disorders assess the effectiveness of systemic therapies in patients undergoing treatment.

Composite Scores and Quality of Life: A New Standard for AD Management

Atopic dermatitis experts evaluate the integration of composite scores and quality of life measures as a new benchmark for comprehensive disease management.

Shari R. Lipner MD, PhD

Articles

Latest Updated Articles